Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Use of Mitomycin C to Lessen Unsightly Scarring Questioned

20.09.2004


Using an animal model, investigators find that Mitomycin C, a common chemotherapy agent, offers limited benefit in reducing keloid or hypertrophic scars.



The tendency for extreme scarring is one reason many African Americans avoid plastic surgery and other surgical incisions. Though surgeons continue to develop less invasive techniques that minimize scarring, other options are needed to help these individuals who are prone to developing keloid scars.

Keloid scars are caused by an overproduction of fibroblasts, the structure on which cells build tissue to heal a wound. The fibroblasts continue to multiply after the wound is filled in and become a raised scar that grows beyond the original wound or point of incision. Dark skinned individuals tend to form keloids more readily than lighter skinned individuals. Hypertrophic scars are more common and occur in all racial groups. They appear raised but stay within the confines of the initial wound or point of incision. Both types of scars can occur through skin injuries such as surgical incisions, traumatic wounds, vaccination sites, burns, chickenpox, acne, or even minor scratches.


Mitomycin C (MMC) is a common chemotherapy agent that inhibits cell growth. It is also known to decrease the proliferation of fibroblasts, an essential element in the development of scar tissue. If too many fibroblasts are produced, a keloid of hypertrophic scar is produced.

Researchers set out to determine if the use of Mitomycin C can reduce keloid or hypertrophic scarring. To do this, they used an animal model that most closely parallels normal wound healing in humans. Clinical observations were used to assess the effect of topical and intradermal MMC on wound healing while evaluating for the presence of the protein, TGF-B1, to determine how MMC works to decrease fibroblast proliferation and scarring.

The authors of the study, “The Effects of Intradermal and Topical Mitomycin C on Wound Healing,” are Glen T. Porter, MD, and Swarupa Gadre, MD, of the University of Texas Medical Branch in Galveston, TX, and Karen Calhoun, MD Chair of University of Missouri Medical School. Their findings are being presented at the American Academy of Otolaryngology-Head and Neck Surgery Foundation Annual Meeting & OTO EXPO, being held September 19-22, 2004, at the Jacob K. Javits Convention Center, New York City, NY.

Methodology: Twenty-four adult male Sprague-Dawley rats (375-400g) were anesthetized and two incisions were placed on the back. Wound treatment was then administered according to randomization to one of the three study groups: injected MMC group, received intradermal injection with 1.0 ml of Mitomycin C (0.5mg/ml) into each wound; topical MMC group, received a four minute application of topical MMC (0.5mg/ml); saline group, received topical or intradermal saline in a similar manner. After treatment each wound was irrigated and closed with sterile staples. Two animals in each study arm were sacrificed at one and two weeks and one and six months after surgery. The wounds were then visually inspected and then a small sample was excised. Each wound was then serially sectioned. One section was sent for microscopic examination (blinded) with H&E staining and TGF-B1-specific immunohistochemical staining. Using a tensiometer, the remaining wound sections were tested to evaluate the force necessary to cause wound dehiscence (unblinded).

Results were evaluated using the SPSS software. Kruskal-Wallis and Mann-Whitney tests were used for statistical comparison. Study animals were treated in accordance to federal and state-mandated standards.

Results: Wound evaluation at the time of harvest showed an 88 percent (7/8) incidence of skin necrosis in the intradermal MMC group. Frank necrosis was noted in the wounds harvested at one and two weeks. Wounds harvested at one and six months showed corresponding areas of scarring consistent with areas of healing by secondary intention. No skin necrosis was noted in topical MMC and control animals. Wounds treated with topical MMC had poorer wound integrity compared with controls at one week (p<.001), two weeks (p<.001), one month (p<.001) and six months (p<.001). When compared to controls this represents a 3-4-fold decrease in wound strength at each time period. Intradermal MMC showed poorer wound integrity at two weeks (p<.001), one month (p<.001), and six months (p<.001) when compared with controls. Again, this represented at least a 3-fold decrease for the latter three time periods. There was a significant difference in wound strength when comparing topical and intradermal MMC only at the first week (p<.001) with injected wounds being weaker.

Blinded evaluation of H&E and immunohistochemical staining of wound sections showed no consistently identifiable difference between wounds in the three treatment groups. TGF-?1 was not consistently identified in any group.

Conclusions: The results of this study indicate that the application of MMC, whether topical or injected, will result in decreased wound strength which is still significantly different at six months after wounding. Intradermal injection appears to have no more affect on wound strength than topical, but carries an increased risk of skin necrosis. No consistently identifiable changes in histology or TGF-B1 expression was noted, which does not mean that TGF-B1 is not involved, only that the instrument of detection did not pick it up as the protein may not be present in quantities large enough to detect with immunohistochemical staining. This data suggests cautious use of MMC in clinical situations where wound breaking strength is critical. Intradermal MMC should be avoided as skin necrosis and scarring may result. Further study in humans is necessary to determine the effect of MMC on keloid and hypertrphic scars.

| newswise
Further information:
http://www.entnet.org

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>